Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 59, Issue 4, Pages 2432-2434Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.04568-14
Keywords
-
Categories
Funding
- CEMPRA Pharmaceuticals (Chapel Hill, NC)
Ask authors/readers for more resources
Solithromycin, a next-generation macrolide and novel fluoroketolide, was tested against a 2012 collection of serotyped U.S. macrolide-resistant Streptococcus pneumoniae isolates associated with community-acquired bacterial pneumonia (CABP). Against all 272 isolates, solithromycin demonstrated high potency (MIC50/90, 0.06/0.25 mu g/ml), and it inhibited all strains at MICs of <= 0.5 mu g/ml, including the two most prevalent macrolide-resistant serotypes (19A and 35B). These data support the continued clinical development of solithromycin for the treatment of multidrug-resistant CABP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available